Amgen Inc.
AMGNHealthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.
- Revenue
- +8.45%
- EPS
- +19.4%
- Free cash flow
- −14.0%
- Total debt
- −1.06%
Quarter to September 2026, against a year earlier
Follow AMGN
Alert me
Amgen Inc. (AMGN) P/S ratio
As of Nov 19, 2026, Amgen Inc. (AMGN) trades at a P/S ratio of 6.1×. Over the past ten years it has ranged from 4.1× (May 2025) to 6.7× (November 2026); the current reading is higher than 96% of that period. That is above the Drug Manufacturers General industry median of 3.4× and above the Healthcare sector median of 3.4×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 4.8× | 14.42% |
| FY2024 | 4.2× | (25.81%) |
| FY2023 | 5.6× | 5.54% |
| FY2022 | 5.3× | 8.34% |
| FY2021 | 4.9× | (6.86%) |
| FY2020 | 5.3× | (15.11%) |
| FY2019 | 6.2× | 15.21% |
| FY2018 | 5.4× | (4.31%) |
| FY2017 | 5.7× | 15.47% |
| FY2016 | 4.9× | (13.67%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 5.9× | 14.19% |
| Jun 2026 | 5.1× | 0.55% |
| Mar 2026 | 5.1× | 6.54% |
| Dec 2025 | 4.8× | 13.52% |
| 43 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| BMY Bristol Myers Squibb Company compare | 2.4× |
| PFE Pfizer Inc. compare | 2.5× |
| NVO Novo Nordisk A/S compare | 3.3× |
| AZN AstraZeneca PLC compare | 4.4× |
| MRK Merck & Co., Inc. compare | 4.9× |
| NVS Novartis AG compare | 5.0× |
| AMGN Amgen Inc. | 6.1× |
| GILD Gilead Sciences, Inc. compare | 6.7× |
| ABBV AbbVie Inc. compare | 7.6× |
| Drug Manufacturers General industry median | 3.4× |
| Healthcare sector median | 3.4× |
| Market median | 1.8× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on AMGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement